drugset / Trial / NCT04646694

The Ketamine for Acute Postoperative Analgesia (KAPA) Trial

NCT04646694

Phase 3 Completed 40 enrolled University Health Network, Toronto
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Postoperative pain remains an important challenge for both patients and clinicians. Despite advances in pain management techniques, many patients continue to describe their pain as moderate to severe immediately after surgery. Poor postoperative pain control is associated with increased morbidity, functional impairment, and higher health care costs. While opioids currently represent the mainstay of treating surgical pain, their use is associated with significant side effects including respiratory depression, delayed recovery of bowel function as well as the potential for long-term use. Therefore, there is an urgent need to find new pain relievers with a safer side effect profiles. One such drug that has been receiving increasing attention is ketamine. Previous studies have focused on using intravenous ketamine postoperatively which requires a monitored setting but have ignored the oral form. By using the oral route of administration, ketamine could potentially be used by patients in a less resource-intensive manner with similar efficacy. Therefore, Investigators propose to conduct the Ketamine for Acute Postoperative Analgesia (KAPA) pilot study to examine the role of oral ketamine in improving recovery after spine surgery.

Timeline

Start
2020-11-17
Primary completion
2023-03-31
Completion
2023-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 30 mg Oral

Indications

No indication recorded.